MedTrace Logo

Efficacy and Safety of Navarixin (SCH 527123) in Participants With Allergen-Induced Asthma (P05363)

NCT00688467 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2019-01-02

Study results available
· View outcomes & findings →

Summary

Evaluation of treatment in participants with mild asthma.

Conditions

Interventions

DRUG

Navarixin

30 mg capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2

DRUG

Placebo

Matching capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-01
Primary Completion
2009-03-01
Completion
2009-03-01

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00688467 on ClinicalTrials.gov